UK MHRA Approves Icotyde for Moderate to Severe Plaque Psoriasis

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved icotrokinra hydrochloride (Icotyde) as a new oral treatment for adults and adolescents aged 12 and older with moderate to severe plaque psoriasis who are candidates for systemic therapy. The approval, granted on October 23, 2026, was supported by data from four Phase 3 clinical trials involving 2,500 individuals, demonstrating efficacy compared to placebo at week 16. The medicine works by selectively binding to and blocking the IL-23 receptor.